Publication of 2017 Registration Document

Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced the publication of the Company’s 2017 Registration Document.

The 2016 Registration Document, filed with the French Market Authorities (Autorité des Marchés Financiers) on April 25, 2018, is available to the public free of charge upon request, as per current legal regulations, at on the Company’s website: http://www.onxeo.com/en/investisseurs/resultats-et-publications.

Copies of the Registration Document are also available at the head offices of Onxeo – 49 Boulevard du Général Martial Valin, 75015 Paris – and

The annual financial report, the report on corporate governance, as well as the auditors’ reports and information on the fees paid to the statutory auditors in 2017 are included in this Registration Document.

250418_PR_ONXEO_availability_DDR_2017_vf